Ann: September 2021 Quarterly Activities Report and Appendix 4C, page-9

We seem to be adding patents at a rapid rate, Veyonda's pharmacology is starting to take shape as both an anti-inflammatory/cytokine storm blocker and it's blocking of Sphingosine-1-phosphate in cancer cells which augments the activity of checkpoint inhibitors, radiation and chemotherapy.
We are currently stuck with the worst patients and providing great results. To me IONIC is the most exciting but as always with biotechs we are on the cusp of the next big thing, I think we will be partnering within 6 months based on Lupin results and our ongoing patent protection. I have topped up on Noxo in anticipation.

GLTAH